Edinburgh, 18th October, 2018 / Synpromics is pleased to announce positive data presented today by a key partner, uniQure (NASDAQ:QURE), at the European Society of Gene and Cell Therapy conference in Lausanne, Switzerland. The study used uniQure’s next-generation liver-directed gene therapy system that incorporates a short, highly-selective and powerful liver promoter that was developed by Synpromics.


Edinburgh, 17th October, 2018 / Synpromics is today unveiling its novel drug-regulatable promoter platform at the European Society of Cell and Gene Therapy (ESGCT) congress in Lausanne, Switzerland. The company is showcasing data generated from its innovative liver selective inducible and repressible synthetic promoter systems that are tightly controlled by FDA-approved small molecule drugs.


Scotland is home to a flourishing life science industry with government supported plans to increase its size to £8bn by 2025. Bioclusters in Edinburgh, Glasgow, Aberdeen and Dundee provide the expertise, facilities and collaboration opportunities required to enable this growth.


Edinburgh, UK, 22nd June 2018 / Synpromics, the leader in gene control, is delighted to announce that David Venables, CEO of the Company, has won the ‘Disruptor’ category of Scotland’s EY Entrepreneur Of The Year 2018. 


In May, Synpromics attended the ASGCT annual general meeting in Chicago. After a slightly delayed arrival of the exhibition stands (having got temporarily lost somewhere over the Atlantic!), the Synpromics delegation enjoyed a few days of interesting presentations around the future of gene and cell therapy, as well as making some great connections with fellow biotech professionals. Synpromics were also able to introduce numerous booth visitors to a renowned Scottish delicacy, the Tunnocks Teacake – 500 were consumed over the course of the conference!